JP2013543869A - Ｂ細胞リンパ腫のための併用療法 - Google Patents

Ｂ細胞リンパ腫のための併用療法 Download PDF

Info

Publication number
JP2013543869A
JP2013543869A JP2013538963A JP2013538963A JP2013543869A JP 2013543869 A JP2013543869 A JP 2013543869A JP 2013538963 A JP2013538963 A JP 2013538963A JP 2013538963 A JP2013538963 A JP 2013538963A JP 2013543869 A JP2013543869 A JP 2013543869A
Authority
JP
Japan
Prior art keywords
antibody
seq
amino acid
acid sequence
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013538963A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013543869A5 (enExample
Inventor
ロナルド・ハーブスト
エリザベス・ケイ・ウォード
キャスリーン・フィリップス・マッキーバー
Original Assignee
メディミューン，エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メディミューン，エルエルシー filed Critical メディミューン，エルエルシー
Publication of JP2013543869A publication Critical patent/JP2013543869A/ja
Publication of JP2013543869A5 publication Critical patent/JP2013543869A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2013538963A 2010-11-15 2011-11-14 Ｂ細胞リンパ腫のための併用療法 Pending JP2013543869A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41377110P 2010-11-15 2010-11-15
US61/413,771 2010-11-15
PCT/US2011/060520 WO2012067981A1 (en) 2010-11-15 2011-11-14 Combination therapy for b cell lymphomas

Publications (2)

Publication Number Publication Date
JP2013543869A true JP2013543869A (ja) 2013-12-09
JP2013543869A5 JP2013543869A5 (enExample) 2015-01-15

Family

ID=46084355

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013538963A Pending JP2013543869A (ja) 2010-11-15 2011-11-14 Ｂ細胞リンパ腫のための併用療法

Country Status (11)

Country Link
US (1) US20130330328A1 (enExample)
EP (1) EP2640416A4 (enExample)
JP (1) JP2013543869A (enExample)
KR (1) KR20130130726A (enExample)
CN (1) CN103228291A (enExample)
AU (1) AU2011329161A1 (enExample)
CA (1) CA2817842A1 (enExample)
MX (1) MX2013005270A (enExample)
RU (1) RU2013127115A (enExample)
SG (1) SG190254A1 (enExample)
WO (1) WO2012067981A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019519770A (ja) * 2016-05-30 2019-07-11 モルフォシス・アーゲー 患者における抗ｃｄ１９治療の治療的有用性を予測するための方法
JP2020526568A (ja) * 2017-07-10 2020-08-31 インターナショナル−ドラッグ−ディベロップメント−バイオテック 抗ｃｄ２０抗体または化学療法薬と併用して非フコシル化アポトーシス促進性抗ｃｄ１９抗体を用いるｂ細胞悪性の治療
JP2022545041A (ja) * 2019-08-21 2022-10-24 ジョイント－ストック カンパニー “ジェネリウム” Ｃｄ３結合のための相補性決定領域およびそのｃｄｒを含む二重特異性抗原結合分子

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250215081A1 (en) * 2020-11-06 2025-07-03 Novartis Ag Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008530142A (ja) * 2005-02-15 2008-08-07 デューク ユニバーシティ 抗ｃｄ１９抗体および腫瘍学における使用
JP2009539413A (ja) * 2006-06-12 2009-11-19 トゥルビオン・ファーマシューティカルズ・インコーポレーテッド エフェクター機能を有する単鎖多価結合タンパク質
JP2010502232A (ja) * 2006-09-08 2010-01-28 メディミューン，エルエルシー ヒト化抗ｃｄ１９抗体ならびに癌、移植および自己免疫疾患の治療におけるその使用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008530142A (ja) * 2005-02-15 2008-08-07 デューク ユニバーシティ 抗ｃｄ１９抗体および腫瘍学における使用
JP2009539413A (ja) * 2006-06-12 2009-11-19 トゥルビオン・ファーマシューティカルズ・インコーポレーテッド エフェクター機能を有する単鎖多価結合タンパク質
JP2010502232A (ja) * 2006-09-08 2010-01-28 メディミューン，エルエルシー ヒト化抗ｃｄ１９抗体ならびに癌、移植および自己免疫疾患の治療におけるその使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WARD, BETH K. ET AL.: "A glycoengineered anti-CD19 antibody (MEDI-551) is effective as monotherapy or in combination treatm", MOLECULAR CANCER THERAPEUTICS, vol. Vol.8, No.12, Suppl.1., JPN6015038295, 10 December 2009 (2009-12-10), pages 186, ISSN: 0003160310 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019519770A (ja) * 2016-05-30 2019-07-11 モルフォシス・アーゲー 患者における抗ｃｄ１９治療の治療的有用性を予測するための方法
JP7066639B2 (ja) 2016-05-30 2022-05-13 モルフォシス・アーゲー 患者における抗ｃｄ１９治療の治療的有用性を予測するための方法
JP2022119764A (ja) * 2016-05-30 2022-08-17 モルフォシス・アーゲー 患者における抗ｃｄ１９治療の治療的有用性を予測するための方法
JP7511806B2 (ja) 2016-05-30 2024-07-08 インサイト コーポレイション 患者における抗ｃｄ１９治療の治療的有用性を予測するための方法
US12631639B2 (en) 2016-05-30 2026-05-19 Incyte Corporation Methods for predicting therapeutic benefit of anti-CD19 therapy in patients
JP2020526568A (ja) * 2017-07-10 2020-08-31 インターナショナル−ドラッグ−ディベロップメント−バイオテック 抗ｃｄ２０抗体または化学療法薬と併用して非フコシル化アポトーシス促進性抗ｃｄ１９抗体を用いるｂ細胞悪性の治療
JP7279011B2 (ja) 2017-07-10 2023-05-22 インターナショナル－ドラッグ－ディベロップメント－バイオテック 抗ｃｄ２０抗体または化学療法薬と併用して非フコシル化アポトーシス促進性抗ｃｄ１９抗体を用いるｂ細胞悪性の治療
JP2022545041A (ja) * 2019-08-21 2022-10-24 ジョイント－ストック カンパニー “ジェネリウム” Ｃｄ３結合のための相補性決定領域およびそのｃｄｒを含む二重特異性抗原結合分子
JP7366242B2 (ja) 2019-08-21 2023-10-20 ジョイント－ストック カンパニー “ジェネリウム” Ｃｄ３結合のための相補性決定領域およびそのｃｄｒを含む二重特異性抗原結合分子

Also Published As

Publication number Publication date
CN103228291A (zh) 2013-07-31
SG190254A1 (en) 2013-06-28
CA2817842A1 (en) 2012-05-24
EP2640416A4 (en) 2014-04-23
US20130330328A1 (en) 2013-12-12
EP2640416A1 (en) 2013-09-25
WO2012067981A1 (en) 2012-05-24
RU2013127115A (ru) 2014-12-27
KR20130130726A (ko) 2013-12-02
MX2013005270A (es) 2013-10-25
AU2011329161A1 (en) 2013-06-27

Similar Documents

Publication Publication Date Title
US20250011457A1 (en) Combination Therapies with Anti-CD38 Antibodies
JP5559695B2 (ja) 抗ｃｄ４０抗体の使用
CN102666874B (zh) 由于岩藻糖基化程度的改变而表现出改善的效应子功能的含Fc区的多肽及其使用方法
JP2023078356A (ja) 免疫調節Ｆｃ融合タンパク質の抗癌活性の増強
RU2756010C2 (ru) Комбинация антитела к CD19 и ингибитора тирозинкиназы брутона и их применение
US20250195646A1 (en) Combinations and uses thereof
JP2011503098A5 (enExample)
CN103827143A (zh) 抗cd20抗体和抗gm-csf抗体的治疗性组合产品及其用途
EP2782600A1 (en) Combination therapy using anti - cd20 antibody and human il-15
TW202216193A (zh) 包含抗CD19抗體及阻斷SIRPα-CD47先天免疫檢查點之多肽之抗腫瘤組合療法
US20130330328A1 (en) Combination Therapy For B Cell Lymphomas
CN110869391A (zh) 用BET抑制剂,Bcl-2抑制剂和抗CD20抗体的组合疗法
JP7279011B2 (ja) 抗ｃｄ２０抗体または化学療法薬と併用して非フコシル化アポトーシス促進性抗ｃｄ１９抗体を用いるｂ細胞悪性の治療
RU2815679C2 (ru) Комбинированная терапия на основе антитела к cd20 и ингибитора btk
Karlin et al. Obinutuzumab
EA047575B1 (ru) Лечение b-клеточных злокачественных новообразований с использованием афукозилированных проапоптотических анти-cd19 антител в сочетании с анти-cd20 антителами или химиотерапевтическими средствами

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141114

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141114

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150929

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160308